Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): First results from CIBMTR.

View Full Paper
Ask AI
Bookmark
Share

Authors

ETEmily TomasuloUniversity of PennsylvaniaNJNitin JainThe University of Texas MD Anderson Cancer CenterJBJohn C. ByrdUniversity of Cincinnati

Discussion

Loading...

Member takes

Implication

Observational study shows liso-cel improves response rates in patients with relapsed or refractory CLL, suggesting it as a viable treatment option.

Key Points

  • Evaluate the real-world effectiveness and safety of liso-cel in patients with relapsed or refractory chronic lymphocytic leukemia.
  • Observational study of US patients receiving commercial liso-cel between 05/2024 and 09/2025.
  • Analyzed effectiveness outcomes including overall response rate (ORR), complete response (CR) rate, and safety outcomes such as adverse events.
  • Follow-up duration was a median of 6 months.
  • Overall response rate (ORR) was 84% (95% CI: 70–93).
  • Complete response (CR) rate was 55% (95% CI: 39–70), with 81% of CR patients being MRD negative.
  • 6-month nonrelapse mortality (NRM) was 5% (95% CI: 0.8–14).

Cite This Study

Tomasulo et al. (2026) studied this question.

synapsesocial.com/papers/6a192e68fab5b468c441773dhttps://doi.org/10.1200/jco.2026.44.16_suppl.7024
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.2026
  2. 2Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma2026 · 3 citations
  3. 3Efficacy and safety of lisocabtagene maraleucel monotherapy in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis of clinical trials and real-world studies2025 · 1 citations
  4. 4Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR).2024 · 6 citations
  5. 5Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry2025